Gritstone and CEPI expand agreement for SAM vaccine to target SARS-CoV-2 Omicron variant Dec. 7, 2021
Chimeric obtains option to license CORE-NK platform from Case Western Reserve University Dec. 2, 2021
Parvus enters agreement to advance PVT-201 for primary biliary cholangitis Dec. 1, 2021 Parvus Therapeutics has announced an agreement with National Resilience for the tech transfer, scale-up and GMP manufacturing of PVT-201, Parvus' lead Navacim drug candidate being developed to treat primary biliary cholangitis.Read More
Artizan and Biohaven begin therapeutic discovery and development program in Parkinson's Nov. 19, 2021
RSS